Compile Data Set for Download or QSAR
maximum 50k data
Found 92 of ic50 for UniProtKB: P10415
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571527((rac)-(rac-15)-benzyl-4-chloro-3-ethyl-7-{3-[(6-fl...)
Affinity DataIC50:  1.22E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571495((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.32E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571496((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.41E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571472((−)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{...)
Affinity DataIC50:  1.46E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571475((+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluor...)
Affinity DataIC50:  1.51E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571488((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.59E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571474((rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[...)
Affinity DataIC50:  1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571469((+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-...)
Affinity DataIC50:  1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50:  1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572222((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571470((−)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphtha...)
Affinity DataIC50:  1.78E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571477((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.81E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571476((−)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6...)
Affinity DataIC50:  1.83E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571463((rac)-4-Chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-...)
Affinity DataIC50:  1.86E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572202((rac)-4-chloro-12,12-difluoro-2,3-dimethyl-7-{3-[(...)
Affinity DataIC50:  1.88E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50:  1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50:  1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571479((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50:  1.93E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571510((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.96E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169((rac)-4-chloro-3-ethyl-2,14-dimethyl-7-[3-(naphtha...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572173(4-chloro-2,3-dimethyl-7-[3-(naphthalen-1-yloxy)pro...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572175((rac)-12-chloro-10,11-dimethyl-1-[3-(naphthalen-1-...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572176((rac)-12-chloro-7,10,11-trimethyl-1-[3-(naphthalen...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572178((+)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]pr...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572181((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572184((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572186((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572189((rac)-(11Z)-4-chloro-3-ethyl-14-methyl-1-[2-(morph...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572192((rac)-4-chloro-3-ethyl-14-methyl-1-[2-(morpholin-4...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572196((+)-4-chloro-3-methyl-2-[3-(4-methylpiperazin-1-yl...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572198((rac)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572201((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572205((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572216((rac)-4-chloro-2,3,15-trimethyl-7-{3-[(naphthalen-...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572216((rac)-4-chloro-2,3,15-trimethyl-7-{3-[(naphthalen-...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572222((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572222((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571440((rac)-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571443((rac)-4-fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571443((rac)-4-fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571446((rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571446((rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571449((rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571449((rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571449((rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571452((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: